Rare Disease Spotlight

Fragile X Syndrome

The most common inherited cause of intellectual disability, caused by mutations in the FMR1 gene on the X chromosome.

Connection: Rare genetic cause of intellectual & mental-health impact

Overview

Fragile X syndrome (FXS) is the most common inherited cause of intellectual disability and the most common single-gene cause of autism spectrum disorder. It's caused by a CGG repeat expansion and then methylation-driven silencing of the FMR1 gene on the X chromosome. Prevalence is around 1 in 5,000 males and 1 in 8,000 females, and females generally show milder and more variable features because they have a second X chromosome doing some of the work.

Impact

Boys with FXS usually have moderate to severe intellectual disability, language delay, autism features, anxiety, ADHD, aggression, and sleep disturbance, while girls often have milder learning differences and high rates of anxiety. Families take on lifelong caregiving and educational advocacy, and premutation carriers face their own distinct risks, including fragile X-associated tremor/ataxia syndrome (FXTAS) and primary ovarian insufficiency (FXPOI), both of which shape genetic counseling across generations.

Medical Overview

FXS is caused by a CGG repeat expansion in the 5' untranslated region of FMR1 (typically more than 200 repeats, called the "full mutation"), which leads to hypermethylation, silencing of the gene, and loss of FMRP, an RNA-binding protein that's critical for how synapses adapt and learn. Clinical features include intellectual disability, autistic traits, language delay, characteristic facial features (long face, prominent ears), macroorchidism (enlarged testicles) after puberty in males, hyperactivity, anxiety, and seizures in a subset of patients. Diagnosis uses molecular testing (Southern blot, triplet-repeat PCR, methylation-specific PCR or MS-MLPA) to figure out both the repeat size and the methylation status. Newer optical genome mapping techniques are starting to show up too. Management is multimodal and symptom-targeted: early behavioral and educational intervention, speech/OT/PT, SSRIs and stimulants for behavioral symptoms, antiepileptics, and treatment of coexisting autism and anxiety. Investigational therapies aimed at metabotropic glutamate receptor 5 (mGluR5) pathways and GABAergic signaling are still under study, and nothing disease-modifying is approved yet.

References

Protic DD, et al.. Fragile X Syndrome: From Molecular Aspect to Clinical Treatment . International Journal of Molecular Sciences . 2022.